Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of Company Stock

Key Points

• Vericel insider Sean Flynn sold 15,000 shares for $778,800 at an average price of $51.92, leaving him with 1,990 shares—an 88.29% reduction in his holdings.
• Third-quarter results topped estimates: revenue rose 26.5% year over year to $85.37 million, and earnings were $0.27 per share versus a $0.06 consensus estimate. The company also raised its 2026 revenue guidance to $344–$346 million.
• Analyst sentiment was moderately positive: HC Wainwright raised its price target to $75 and reaffirmed a Buy rating; the stock’s consensus rating was Moderate Buy, with a $60.80 target price.

Vericel Corporation (NASDAQ:VCEL - Get Free Report) insider Sean Flynn sold 15,000 shares of the company's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $51.92, for a total transaction of $778,800.00. Following the completion of the sale, the insider directly owned 1,990 shares in the company, valued at $103,320.80. This represents a 88.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vericel Price Performance

NASDAQ VCEL traded up $2.84 during trading hours on Friday, reaching $54.62. 1,612,192 shares of the company's stock traded hands, compared to its average volume of 598,922. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $55.60. The firm has a market cap of $2.80 billion, a PE ratio of 116.22 and a beta of 1.08. The firm has a 50-day simple moving average of $40.74 and a 200 day simple moving average of $38.80.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel's quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Sell-side analysts forecast that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Vericel in the 2nd quarter worth $360,023,000. William Blair Investment Management LLC bought a new stake in shares of Vericel in the second quarter worth $88,662,000. Bank of America Corp DE purchased a new stake in Vericel during the second quarter valued at $45,210,000. TimesSquare Capital Management LLC purchased a new stake in Vericel during the second quarter valued at $24,463,000. Finally, Osterweis Capital Management Inc. purchased a new stake in Vericel during the second quarter valued at $17,723,000.

Vericel News Summary

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on VCEL shares. HC Wainwright increased their target price on Vericel from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Friday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Vericel in a research report on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research report on Thursday, July 30th. Finally, Truist Financial set a $65.00 price objective on shares of Vericel in a research note on Friday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.